Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2020-11-04 Regulatory Filings
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Mauna Kea Technologies dated November 4, 2020, announcing the publication of two clinical studies (a meta-analysis and a Delphi consensus report) regarding their Cellvizio product for pancreatic cysts. The text explicitly states that these publications 'have been published' ('annonce aujourd'hui la parution de deux publications'). Since the document is an announcement about the release of external reports rather than the reports themselves, and it is a general corporate update/press release format, it fits best under the 'Report Publication Announcement' (RPA) category, as per Rule 2 (Menu vs Meal Rule). It is not a formal regulatory filing like 10-K or IR, nor is it a transcript or a specific financial event report.
2020-11-04 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release from Mauna Kea Technologies announcing the publication of two new scientific documents: a meta-analysis and an international Delphi consensus report regarding the use of their Cellvizio platform for pancreatic cyst evaluation. Since the document itself is an announcement about the release of external reports (a meta-analysis and a consensus report) rather than the full regulatory filing (like 10-K, IR, or AR), and it is not a standard earnings release (ER) or a general regulatory filing (RNS), it best fits the category for announcements related to specific company activities or publications. Given the options, this is an announcement of new scientific/clinical evidence, which often falls under general Investor Relations material. However, none of the codes perfectly capture 'Scientific Publication Announcement'. We must choose the closest fit. It is not a standard financial report (10-K, IR, ER, MRQ). It is not a management change (MANG) or a dividend notice (DIV). It is an announcement of new information for investors. Since it is a press release announcing external, peer-reviewed publications, it is most closely aligned with general corporate news that supports the investment case. If we must choose from the provided list, and recognizing that it is not a formal regulatory filing like 10-K or IR, it functions as a general corporate update. Given the options, 'Regulatory Filings' (RNS) is often used as a broad category for non-standard announcements, but 'Investor Presentation' (IP) or 'Report Publication Announcement' (RPA) might be considered if the content were a presentation or a direct announcement of a formal company report. Since this announces external scientific papers, and not a formal company report like an Annual Report or Interim Report, the most appropriate general category for non-standard, non-financial regulatory news is RNS, or potentially LTR if it were a legal matter, which it is not. Given the context of announcing new evidence, and lacking a specific 'Research Publication' code, RNS (Regulatory Filings - general fallback) is the safest choice for a press release announcing external scientific literature, though it is a weak fit. Re-evaluating: The document is a press release detailing clinical evidence. This type of announcement is often categorized broadly. Since it is not a formal financial report, and the content is about clinical validation, it is a general corporate announcement. I will classify it as RNS as the best general regulatory/corporate announcement fallback.
2020-11-04 English
Rapport financier semestriel 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Rapport Financier Semestriel 2020' (Semi-Annual Financial Report 2020) for Mauna Kea Technologies. It contains detailed financial statements, consolidated accounts under IFRS, a management report (Rapport d'activité), and an audit report summary for the six-month period ending June 30, 2020. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data and analysis for a period shorter than a full fiscal year. H1 2020
2020-10-02 French
Inside Information / News release on accounts, results
Earnings Release Classification · 95% confidence The document is a press release from Mauna Kea Technologies detailing their financial results for the first half of 2020 and preliminary sales for the third quarter of 2020. It includes key financial highlights, tables, and management commentary. While it contains substantive financial data, it is structured as a corporate press release (Earnings Release) rather than a formal, comprehensive Interim Report (which would typically be a longer, regulatory-filed document). Therefore, it fits the definition of an Earnings Release (ER). H1 2020
2020-09-22 English
Informations privilégiées / Communiqué sur comptes, résultats
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half (H1) of 2020, containing detailed financial statements, balance sheet data, and management analysis of the results. It is not merely an announcement of a report, as it provides substantive financial data and tables. Therefore, it is classified as an Interim/Quarterly Report. H1 2020
2020-09-22 French
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is a short announcement dated September 15, 2020, stating that Mauna Kea Technologies will publish its 2020 semi-annual results (résultats semestriels 2020) on September 22, 2020, and will hold a conference call to discuss them. Since the document is short and its primary function is to announce the publication of a report (the semi-annual results) and the associated call, it fits the definition of a Report Publication Announcement (RPA). It is not the comprehensive Interim/Quarterly Report (IR) itself, nor is it the Call Transcript (CT), but rather the notice *about* the upcoming release and call.
2020-09-15 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.